gene therapyBayer’s Ask Bio unit starts Phase II heart failure gene therapyBayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure. more ➔
LabGerman companies to revolutionise lab plastics marketGerman Green Elephant Biotech has launched the world’s first plant-based 96-well microtitre plate on the market. more ➔
financingAMPLY Discovery Ltd bags £1.4m funding to tackle complex diseasesBelfast-based techbio company AMPLY Discovery Ltd announced today will make use of a £1.4m in grant funding to advance its AI-based drug discovery platform. more ➔
financingCambridge university spin-out HutanBio Ltd bags £2.25m seed financingBritish-Malasian marine algae biofuel start-up HutanBio has secured an £2.25m seed investment to produce carbon negative biodiesel in brackish water. more ➔
agri-biotechEU parliament backs deregulation of New Genome TechniquesAfter two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding. … more ➔
partnershipJazz Pharmaceuticals licences KRAS blocker from Redx PharmaJazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules. more ➔
financingSpanish plant-based protein producer Heüra Foods closes Series B financingSpanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution. more ➔
CDMOBiovian and 3P Biopharmaceuticals join forces to create 3PBIOVIANBiovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN. more ➔
RNALonza and Oxford Nanopore collaborate to advance mRNA TherapeuticsTo improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA … more ➔
CRO£26m for Cystic Fibrosis Drug Trial Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors. more ➔
